

MYLAN LABORATORIES INC

Form 8-K

February 28, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15 (d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **February 27, 2007**

**MYLAN LABORATORIES INC.**

(Exact name of registrant as specified in its charter)

**Pennsylvania**

(State or other jurisdiction  
of Incorporation)

**1-9114**

(Commission File  
Number)

**25-1211621**

(I.R.S. Employer  
Identification No.)

**1500 Corporate Drive  
Canonsburg, PA 15317**

(Address of principal executive offices)

**(724) 514-1800**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

**Item 8.01. Other Events.**

On February 27, 2007, Mylan Laboratories Inc., a Pennsylvania corporation (the Company), issued a press release reporting that the district court for the Western District of Pennsylvania had ruled in favor of Pfizer in the Company's pending amlodipine litigation and that the Company plans to immediately appeal the ruling. The Company also announced that it reaffirmed its fiscal 2007 adjusted earnings per diluted share guidance of \$1.50 to \$1.55 as this product was never factored into the Company's fiscal 2007 guidance.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of the registrant dated February 27, 2007.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYLAN LABORATORIES INC.

Date: February 27, 2007

By: /s/ Edward J. Borkowski

Edward J. Borkowski  
Chief Financial Officer

**EXHIBIT INDEX**

Exhibit No.	Description
99.1	Press Release of the registrant dated February 27, 2007.

3